BioPharma Drug Approval
Geneos Launches Global Phase 2 Trial of Personalised Cancer Vaccine to Prevent Liver Cancer Recurrence
Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of neoantigen-based personalized immunotherapy for cancer (PIC), a...
October 23, 2026 | News
Patronus Biotech Secures Australian Approval for First-in-Human Trial of Next-Generation Malaria Vaccines
Bellberry Limited Research Ethics Committee approves first-in-human study in Australia of Patronus Biotech's novel multi-stage virus-like-particle (VLP)-ba...
October 22, 2026 | News
Metabolon Launches AI-Enabled Splash & Ripple to Accelerate Metabolomics-Driven Drug Discovery
New bioinformatics application combines curated metabolite-protein knowledge, advanced network algorithms, interactive exploration, and optional AI interpr...
October 22, 2026 | News
Ascletis Reports Promising Preclinical Data for Once-Weekly Oral Obesity Treatments, Advances US Phase 1 Trial
Ascletis' industry-leading once-weekly oral peptide pipeline covers all four validated targets, with multiple first-in-class fixed-dose combina...
October 21, 2026 | News
PharmaEssentia Accelerates Global Expansion with US and Japan Drug Approvals and US$46 Million Manufacturing Investment
PharmaEssentia Corporation (TWSE: 6446), a Taiwan-based biopharmaceutical company, is expanding its global presence through new drug approvals, clini...
October 21, 2026 | News
Chipscreen Biosciences Secures China IND Approval for First-in-Class Cancer Immunotherapy NW001
Shenzhen Chipscreen Biosciences Co., Ltd. announced that NW001, a first-in-class epigenetic immune-modulating antibody conjugate (EIMAC) co-developed with ...
October 21, 2026 | News
Takeda’s First-in-Class Narcolepsy Drug ORZEYFUL Enters Japan and China Markets Following Regulatory Approvals
ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (...
October 16, 2026 | News
Shanghai Ark Biopharmaceutical Secures US FDA IND Clearance for Phase II Trial of Long-Acting Influenza Prevention Drug AK0406
Shanghai Ark Biopharmaceutical announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new drug (IND) application for AK...
October 14, 2026 | News
Asieris Pharmaceuticals and Theramex Sign Over $250 Million Licensing Deal for Cervical Precancer Therapy CEVIRA
Agreement is expected to grant Theramex exclusive rights to CEVIRA® in Europe, Australia, New Zealand and Turkey, while Asieris retains rights for th...
October 13, 2026 | News
Semaglutide Generics, Six Months In: Every Launch in India, Every Price, and Where China Stands
AT A GLANCE 12 generic makers with a public launch in India, selling 20 brands between them Rs 1,290 lowest stated monthly price, for vials...
October 09, 2026 | Analysis
FDA Expands Lilly’s Jaypirca Approval to First-Line CLL/SLL Treatment
Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirto...
October 06, 2026 | News
Rznomics Secures Positive EMA Opinion for Orphan Designation of RZ-001 in Glioma
Rznomics Inc., a biopharmaceutical company specializing in the development of RNA-based gene therapies, announced that the European Medicines Agency's (EMA...
October 02, 2026 | News
Lilly’s Retatrutide Delivers 20.8% Weight Loss in Phase III Obesity and Type 2 Diabetes Trial
In TRIUMPH-2, participants with obesity and type 2 diabetes taking retatrutide 12 mg lost an average of 49.6 lbs (20.8%) over 80 weeks, with more than half...
October 01, 2026 | News
China Approves Jaypirca Across All Lines of Therapy for CLL/SLL
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...
September 30, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
